Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Preferred Stock Liabilities (2019)

Historic Preferred Stock Liabilities for Kymera Therapeutics (KYMR) over the last 1 years, with Q4 2019 value amounting to $59.9 million.

  • Kymera Therapeutics' Preferred Stock Liabilities changed N/A to $59.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $59.9 million, marking a year-over-year change of. This contributed to the annual value of $59.9 million for FY2019, which is N/A changed from last year.
  • Per Kymera Therapeutics' latest filing, its Preferred Stock Liabilities stood at $59.9 million for Q4 2019.
  • Kymera Therapeutics' Preferred Stock Liabilities' 5-year high stood at $59.9 million during Q4 2019, with a 5-year trough of $38.7 million in Q3 2019.